Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phylodynamics and Molecular Evolution of Hepatitis A Virus During the Years 1957-2021 in Japan.

Journal of medical virology·2026
Same author

Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis.

The American journal of gastroenterology·2026
Same author

Accuracy of Toric Intraocular Lens Formulas in Eyes With Previous Myopic Laser Vision Correction.

Journal of refractive surgery (Thorofare, N.J. : 1995)·2026
Same author

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Journal of gastroenterology and hepatology·2026
Same author

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same journal

Calendar of Courses, Symposiums and Conferences.

The American journal of gastroenterology·2026
Same journal

Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

The American journal of gastroenterology·2026
Same journal

ACG Clinical Guideline: Colonic Diverticulitis.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

2026 CME Information.

The American journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K

Predicting the Risk of Decompensation in Patients With Cirrhosis: A Validated Machine Learning Approach.

Philip J Johnson1, Anton Kalyuzhnyy2,3, Arturas Grauslys2,4

  • 1Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.

The American Journal of Gastroenterology
|March 25, 2026
PubMed
Summary
This summary is machine-generated.

A new machine learning model, RODIC, accurately predicts the risk of liver decompensation in patients with compensated cirrhosis using simple clinical and lab data. This tool aids in early risk stratification for better patient management.

Keywords:
chronic liver diseasecirrhosishepatic decompensationmachine learningrisk stratification

Related Experiment Videos

Last Updated: Mar 27, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K

Area of Science:

  • Hepatology
  • Machine Learning
  • Predictive Analytics

Background:

  • Compensated cirrhosis patients lack simple tools to predict hepatic decompensation.
  • Early prediction is crucial for timely intervention and improved patient outcomes.

Purpose of the Study:

  • To develop and validate a straightforward machine learning model for predicting liver decompensation in compensated cirrhosis.
  • To create a tool utilizing routinely available clinical and laboratory data.

Main Methods:

  • Applied a random forest classifier to clinical and laboratory data from 575 patients in training cohorts (UK, Italy).
  • Validated the model across independent international cohorts totaling over 2,100 patients (Ireland, Egypt, UK, Japan).

Main Results:

  • Developed RODIC (Risk of Decompensation in Cirrhosis), a model based on albumin, bilirubin, and Fib-4 score.
  • Achieved high performance in training (AUC-ROC=0.86, F1=0.82) and validation cohorts (AUC-ROC 0.67-0.80).
  • Model demonstrated effectiveness across diverse cirrhosis etiologies and in HCV patients with sustained virologic response.

Conclusions:

  • A validated machine learning model (RODIC) accurately quantifies decompensation risk in compensated cirrhosis.
  • The model uses readily available clinical and laboratory features, offering a practical tool for risk assessment.